Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human Phase 1/2 study of HMB-001 in Glanzmann thrombasthenia
2023-505995-31-00Phase 2Authorised
- Sponsor
- Hemab Therapeutics
- Start
- Feb 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label trial of sutacimig in Glanzmann thrombasthenia (GT) (3 arms), sponsored by Hemab Therapeutics. Primary endpoints: Safety and tolerability and Preliminary prophylactic effect. Planned start Feb 2024; status: authorised.
02
Drugs
sutacimig
03
Conditions
Glanzmann thrombasthenia (GT)
Beyond the preview
Go deeper on 2023-505995-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505995-31-00.